Blood test after lung tumor surgery to find hidden disease
Part of Cancer, Lungs & breathing clinical trials.
This study uses a special blood test to look for tiny traces of lung cancer after surgery. It aims to find “minimal residual disease,” meaning cancer cells that may still be hiding after your tumor is removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and can sign consent forms
- Your health/activity level is good (ECOG 0 or 1)
- You have non-small cell lung cancer (NSCLC) that is planned for complete surgery
- Your tumor is at least 1 cm and has some solid part on scans
- Your surgical tumor samples (FFPE tissue) must be available for the study’s blood test work
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a blood test called ctDNA to look for leftover lung cancer after surgery. Based on that result, the trial will help decide which treatment approach is best for you and may catch cancer returning earlier.
This study checks whether a special blood test (ctDNA) taken before and after surgery can predict whether non-small cell lung cancer will come back. If it works, it may help doctors spot recurrence earlier and guide follow-up care after tumor removal.
This study tests whether a simple blood test (liquid biopsy) can help doctors monitor for cancer returning after surgery for early-stage lung cancer. It is for people with non-small cell lung cancer that can be removed with surgery.
This trial uses a blood test to look for tiny bits of cancer DNA after treatment. It may help find early signs that lung cancer has come back, so doctors can act sooner.
This trial tests whether a simple blood test (ctDNA) can help doctors decide if you need radiation therapy after lung cancer surgery. The goal is to tailor your treatment to your individual risk, possibly avoiding extra radiation if you don't need it.
This study looks at how tumor and blood biomarker results can guide treatment for people with non-small cell lung cancer (NSCLC). Depending on the cancer stage, it may follow standard-of-care treatment plans around surgery or first-line immunotherapy.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.